Company intelligence / Profile preview

Integrity Acquisition

Camarillo, California, United States

Ownership: Private
Development stage: Other

Overview

Integrity Bio specialized in formulation and fill-finish of hard-to-formulate biologics, processing over 60 large molecule biologic candidates per year for a range of preclinical and clinical-stage programs. After its acquisition by Curia in 2021, Integrity Bio's offerings were integrated to help provide end-to-end biologics services from R&D through clinical fill-finish manufacturing[1][2][5][6][8].

Modalities: ProteinAntibodyLipid nanoparticle delivery therapyPeptidesVaccine
Industry: Contract Manufacturing Organization

Beyond the preview

Go deeper on Integrity Acquisition.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Integrity Acquisition.

Explore the full profile